Bupropion Initiation and Maintenance for Mixed Anxiety and Depression
Start bupropion extended-release (XL) at 150 mg once daily in the morning, increase to 300 mg daily after 4 days if tolerated, and monitor closely for anxiety worsening, particularly in the first 1-2 weeks 1.
Initiation Protocol
Dosing schedule:
- Days 1-4: 150 mg XL once daily in the morning
- Day 5 onward: 300 mg XL once daily in the morning (target maintenance dose)
- Take with or without food; swallow whole—do not crush, divide, or chew 1
The FDA-approved dosing for major depressive disorder allows for rapid titration to the therapeutic dose of 300 mg within 4 days 1. This differs from the smoking cessation protocols that use slower titration schedules 2.
Critical Monitoring Plan
Week 1-2 (most critical period):
- Assess patient within 1-2 weeks of initiation for suicidal ideation, agitation, irritability, or unusual behavioral changes 3, 1
- Specifically monitor for anxiety worsening or emergence of new anxiety symptoms
- Screen for insomnia (common early side effect that can exacerbate anxiety)
Weeks 2-8:
- Evaluate therapeutic response at 6-8 weeks; if inadequate response, consider treatment modification 3
- Continue monitoring for anxiety symptoms and tolerability
After 12 weeks:
- Reassess need for continued maintenance treatment and appropriate dosing 1
- For long-term maintenance, continue at the dose that achieved initial response
Special Considerations for Mixed Anxiety-Depression
The anxiety component requires careful attention. While recent evidence suggests bupropion can improve anxiety symptoms in MDD patients 4, and may be comparable to SSRIs in most presentations 4, there is a modest SSRI advantage in highly anxious subgroups 4. The 2022 AGA guideline notes bupropion is "reasonable to prioritize for appropriate patients with depressed mood" 5, and emerging data from 2025 indicate it does not typically worsen anxiety on validated measures 6, 4.
However, bupropion's activating properties can provoke anxiety, particularly at higher doses 6. If anxiety worsens significantly in the first 1-2 weeks:
- Consider holding at 150 mg daily rather than increasing to 300 mg
- If anxiety remains problematic at 150 mg, discontinue and switch to an SSRI/SNRI
- Do not use bupropion in patients with severe, agitated anxiety 7
Contraindications and Safety Screening
Absolute contraindications:
- Seizure disorder or history of seizures 2, 5, 1
- Current or prior diagnosis of bulimia or anorexia nervosa 1
- Abrupt discontinuation of alcohol, benzodiazepines, barbiturates, or antiepileptic drugs 1
- Use of MAOIs within 14 days 1
- Uncontrolled hypertension 5
Screen for:
- History of head trauma, brain metastases, or other factors lowering seizure threshold 2, 5
- Current opioid use (if using naltrexone-bupropion combination) 5
- Hepatic impairment: reduce to 150 mg every other day if moderate-severe (Child-Pugh 7-15) 1
- Renal impairment: consider dose/frequency reduction if GFR <90 mL/min 1
Practical Management Tips
Minimize insomnia risk:
- Administer in the morning only (not late in day) 5
- If insomnia develops, ensure patient is not taking dose after early afternoon
Advantages in this patient:
- Lower risk of sexual dysfunction compared to SSRIs 3, 8
- No weight gain (may cause modest weight loss) 8
- Activating properties may help with energy/motivation deficits 7
- At 300 mg daily, effective for long-term treatment of recurrent depression 5
Common manageable side effects:
- Dry mouth, transient stomach discomfort, headache 9
- These typically improve with continued use
Duration of Treatment
Acute episodes of depression require several months or longer of treatment beyond initial response 1. The dose needed for maintenance is typically the same as the dose that provided initial response. Periodically reassess the need for continued treatment 1.
When discontinuing:
- Taper from 300 mg to 150 mg daily before complete discontinuation 1
- This minimizes withdrawal symptoms
Key Clinical Pitfall
The most common error is failing to recognize that bupropion may not be optimal for patients with severe, prominent anxiety symptoms at baseline. While it can work well for mild-to-moderate anxiety comorbid with depression 6, 4, SSRIs show modest superiority in highly anxious presentations 4. If anxiety is the dominant feature or if the patient has agitated depression, start with an SSRI/SNRI instead 7, 10.